RPL17 and Patent ductus arteriosus: Although still ongoing, interim analysis of a combination of a CD40 agonist, anti-PD-1, and standard of care chemotherapy (gemcitabine + abraxane) induced objective responses in over 50% of advanced PDA patients (37).